CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)
VA Office of Research and Development
2,540 participants
May 22, 2024
INTERVENTIONAL
Conditions
Summary
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
Eligibility
Inclusion Criteria2
- On hemodialysis
- Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol
Exclusion Criteria5
- Impaired decision-making capacity
- Patients not receiving carvedilol who have a history of asthma
- known hypersensitivity to any component of either drug
- Provider unwilling to sign a new medication order for a randomized patient
- No surrogate consent will be allowed
Interventions
a dialyzable, beta-1 selective beta blocker
a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05931276